Table 2.
Univariate and multivariate analysis of DFS and OS in the validation sets of patients with PDAC
| Variables | DFS | OS | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |
| Univariate analysis | ||||
| Age (>62 vs. ≤62) | 1.034 (0.682-1.491) | 0.922 | 1.008 (0.757-1.514) | 0.621 |
| Gender (male vs. female) | 0.917 (0.434-1.264) | 0.085 | 1.019 (0.716-1.884) | 0.135 |
| Tumor location (head/body vs. tail) | 1.072 (0.714-1.455) | 0.863 | 0.933 (0.487-1.534) | 0.757 |
| Neural invasion (yes vs. no) | 1.152 (0.853-1.865) | 0.742 | 1.014 (0.423-1.138) | 0.608 |
| Microvascular invasion (yes vs. no) | 1.675 (1.132-2.524) | 0.022 | 1.769 (1.058-2.974) | 0.011 |
| Differentiation (Poorly vs. well+moderately) | 2.033 (1.854-4.358) | 0.025 | 2.141 (1.573-3.864) | 0.031 |
| 8th edition TNM stage ( I/ II/ III) | 3.013 (2.172-4.056) | <0.001 | 2.863 (1.368-5.477) | <0.001 |
| CA19-9 (U/mL, >37 vs. ≤37) | 1.324 (0.638-2.265) | 0.029 | 1.784 (1.008-2.339) | 0.179 |
| SRPX2 (positive vs. negative) | 3.127 (1.484-5.326) | <0.001 | 1.667 (1.067-2.746) | 0.021 |
| RAB31 (positive vs. negative) | 2.434 (1.228-4.017) | <0.001 | 1.991 (1.164-3.065) | 0.002 |
| SRPX2+RAB31 (positive vs. negative) | 3.983 (2.268-6.157) | <0.001 | 4.123 (2.667-7.403) | <0.001 |
| Multivariate analysis | ||||
| 8th edition TNM stage ( I/ II/ III) | 2.938 (1.835-4.027) | <0.001 | 2.551 (1.426-3.856) | <0.001 |
| SRPX2 (positive vs. negative) | 2.037 (1.146-4.235) | 0.004 | 1.739 (1.004-3.316) | 0.037 |
| SRPX2+RAB31 (positive vs. negative) | 3.929 (2.908-5.456) | <0.001 | 3.436 (2.081-6.143) | <0.001 |
P < 0.05 was considered statistically significant